Dr. Haas is Founder and CEO of Orion Bionetworks. Orion Bionetworks, based in Cambridge, MA, is a non-profit research organization whose mission is to harness the power of computer modeling and high-dimensional biomarker, biosensor and phenotypic data to predict the mechanism and course of brain disorders and accelerate the search for cures.
She served 3 years as Chief Science and Technology Officer for One Mind for Research, a nonprofit organization launched in May 2012 by Patrick J Kennedy. She orchestrated the launch of One Mind’s seminal programs, Apollo, an informatics research portal and, Gemini, an international TBI/PTSD research program.
Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in medical marketing, full clinical development, early development, and translational and biomarker sciences in psychiatry and neurology. She successfully filed NDAs in the US and Europe for risperidone indications in Autism, Adolescent Schizophrenia, Juvenile Bipolar Disorder and Conduct Disorders. She also led Development Teams evaluating compounds for Depression, Neuropathic Pain, Epilepsy, and Migraine Disorder.
As an “intrapreneur” at J&J she established the first Neuroscience Translational Medicine & Integrative Solutions department, and co-founded the first Companion Diagnostics Center of Excellence as well as J&J’s Healthcare Innovation team. She serves on several advisory boards including the International Neuroinformatics Coordinating Facility, Brain Canada, Pear Therapeutics and IMEC for nanoelectronics.
Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, New Jersey, and her MD PhD with distinction in neuroscience from Albert Einstein College of Medicine, New York.